输尿管内支架对下尿路尿动力学的影响

目的：了解留置输尿管内支架对膀胱、尿道功能的影响，不同材料的支架管对下尿路功能的影响是否有差异。方法：据术后是否留置输尿管内支架将患者分组，在术前对患者进行尿动力学检测，并分别在术后3～7d和术后约1个月重复同样的检查。结果：留置PVC内支架者，术前、术后3—7d、术后1个月比较显示：排尿的初始感容量（FDV）、排尿的正常感容量（NDV）、膀胱的顺应性（BC）三项指标差异均有显著性；留置硅胶内支架者，术前、术后3—7d、术后1个月比较显示：FDV、NDV两项指标差异有显著性。结论：留置PVC内支架，可致膀胱的感觉过敏，顺应性下降，而留置硅胶内支架仅见过敏感膀胱。     

口服避孕药和肿瘤

美国自1960年开始应用复合型口服避孕药(OC)。现在世界上约有5500万(其中美国约800～1000万)妇女使用OC。显然,对这样广泛应用的药物必须权衡其利弊。对OC和人类肿瘤的关系的评价存在一些问题:①通常没有合适的动物模型;②肿瘤一般有较长的潜伏期,从接触致癌剂到发生肿瘤约需15年;③年轻妇女恶性肿瘤发生率低;④肿瘤有多种病源学影响如遗传、文化、地理、环境等。每一种甾体避孕药在临床应用前先要进行几种动物试验,这些动物试验的结果仅提供某一种动物的致癌证据,从一种动物结论推论到另一种动物是不确切的。动物实验的结论不能完全推论到人。人群的主要研究方法包括各种流行病学研究,常用方法为:①病例报告(肿瘤登记);②发病率和转归;③病例对照研究;④定群研究。     

金属支架植入治疗上尿路闭锁的中期结果

目的评价金属支架植入治疗上尿路闭锁的中期疗效。方法1995年10月至1998年12月，采用金属支架永久植入治疗上尿路闭锁患者13例，其中肾盂输尿管连接部闭锁8例，肾下盏输尿管吻合口闭锁3例，输尿管上段闭锁和输尿管膀膀吻合口闭锁各1例。闭锁长度1．0～3．6cm。采用影像学方法定期随访，必要时行输尿管镜检查。结果13例术后随访1～9年，平均92个月。输尿管引流通畅6例，需辅助停留输尿管内支架管、换管时见支架处上皮覆盖完全3例，因肾功能进行性恶化而行肾切除2例，因肾积脓感染无法控制而取出金属支架2例。3例患者分别于置管后4、6、6个月发现支架内肉芽组织生长，用钬激光汽化肉芽组织。其中1例4个月后又出现肉芽组织生长，再用钬激光汽化后长期留置双J管。2例患者于置管术后28、32个月并发支架近端结石，分别用微创经皮取石术和输尿管镜取出。结论金属支架植入治疗上尿路闭锁安全、有效，中期结果满意，其对上尿路动力学的影响尚需进一步研究。     

复式脉冲低能量ESWL治疗肾结石769例报告

目的探讨复式脉冲HB-V型低能量体外冲击波碎石机治疗肾结石的治疗效果.方法采用复式脉冲HB-ESWL-VG型低能量碎石机治疗直径<2.0 cm的各类肾结石769例，治疗工作电压3～9 kV，平均冲击次数2 300次.结果肾盏结石总粉碎率为97.4%，其中上中盏结石复打率为13.1%，术后3个月排净率为89.4%，下盏结石复打率为17.3%，排净率为81.5%；肾盂结石粉碎率为98.3%，复打率为6.1%，术后3个月排净率为93.0%.结论复式脉冲低能量ESWL治疗肾结石具有治疗成功率高、复打率低、无严重并发症、副作用少之优点.     

High prevalence of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity

It has been reported that hepatitis B virus (HBV) mutants carrying mutations in the pre-S region can be found in infected patients. In this study, we investigated the prevalence of the HBV variant with the pre-S mutant in different geographic regions, including countries with low and high levels of endemic HBV infection, and analyzed the correlation with clinical findings. We examined 387 HBV DNA-positive serum samples from individuals among 12 countries, consisting of Vietnam, Myanmar, Thailand, China, Korea, Nepal, Japan, Russia, Spain, United States, Bolivia, and Ghana. HBV pre-S mutants were detected in 71 (18.3%) of 387 serum samples tested. This mutant was the most prevalent in Vietnam (36%), followed by Nepal (27.3%), Myanmar (23.3%), China (22.4%), Korea (14.3%), Thailand (10.5%), Japan (7.7%), and Ghana (4.3%). In contrast, no case with this mutation was found in Russia, Spain, United States, and Bolivia. Among the HBV deletion mutations, 15.5% (11 of 71) occurred in the pre-S1 and 46.5% (33 of 71) in the pre-S2 regions. Eight (11.3%) cases had a mutation in both the pre-S1 and pre-S2 regions. In addition, a point mutation at the pre-S2 starting codon was observed in 19 (26.7%) cases. The detection rate of the HBV mutant in patients with hepatocellular carcinoma was significantly higher than in other patients (P < 0.05). Furthermore, these mutants were found more frequently in genotype B (25%) and genotype C (24.5%) than in the other genotypes (P < 0.05). Our results indicated that there was a high prevalence of HBV pre-S mutation in regions of endemic HBV infection in Asia. Furthermore, the pre-S mutation appeared to be correlated with hepatocellular carcinoma and HBV genotypes.     

Efficiency of the ortho VITROS assay for detection of hepatitis C virus-specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios

The clinical significance of specimens with low sample-to-cutoff (S/Co) ratios in the Ortho VITROS chemiluminescence assay (CIA) for detection of antibodies to hepatitis C virus (HCV) was evaluated. In one study of 482 CIA-reactive samples, none of the 83 samples with S/Co ratios of < 5 was HCV RNA positive. In a subsequent study, 332 samples with S/Co ratios of between 1 and 20 were tested with the recombinant immunoblot assay (RIBA). None of the 163 samples with S/Co ratios of < 5 was RIBA positive, 83% were RIBA negative, and 28 samples (18%) were RIBA indeterminate. HCV RNA and/or clinical evidence of hepatitis was not found in the 27 indeterminate cases examined. These results show that over 99% of samples with very low S/Co ratios (< or = 5) have no evidence of HCV infection. Therefore, we suggest that the HCV antibody testing algorithm for the VITROS assay might be modified to eliminate supplemental testing of samples with very low S/Co ratios.